SMC accepts vildagliptin (GalvusT) for restricted use in patients with type 2 diabetes mellitus

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium has accepted vildagliptin (GalvusT)  for restricted use within NHS Scotland in adults with type 2 diabetes mellitus who are inadequately controlled by diet and exercise alone and for whom metformin and sulphonylureas are inappropriate due to contraindications or intolerance.   The drug advice (see link below) summarises the safety and efficacy data considered for this drug in this indication. This notes that in two comparator controlled studies the non-inferiority of vildagliptin to first-line oral anti-diabetic agents was not shown. A network meta-analysis demonstrated similar reductions in HbA1c at 24 weeks for vildagliptin versus another dipeptidyl peptidase 4 (DPP-4) inhibitor.   Please see the link below for further details.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news